Has anyone tried Xyotax? Did it help?
____________
Cell Therapeutics, Inc. (CTI) announced the results of its phase III clinical studies of XYOTAX in non-small cell lung cancer (NSCLC), known as STELLAR 2 and 4. The studies were designed to determine if XYOTAX could increase the overall survival of patients while reducing serious side effects associated with the treatment of first-line or second-line NSCLC. Both trials demonstrated equivalent survival with significant reductions in serious side effects when compared to either docetaxel or gemcitabine/vinorelbine; although they missed their primary endpoints of superior overall survival. XYOTAX was administered in a convenient 10-minute infusion without the requirement for steroids and other premedications.
For more information click on:
http://www.cancercompass.com/cancer-news/1,9000,00.htm